Missing From Trials

African-American patients are missing out on cancer drug clinical trial opportunities, Stat News and ProPublica report. Their analysis of US Food and Drug Administration data found that for most trials for cancer drugs approved since 2015, fewer than 5 percent of the patients who participated were African American, even as African Americans make up 13.4 percent of the US population.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

The Washington Post reports on a Federal Bureau of Investigation plan to place rapid DNA analyzers at booking stations around the country.

In an editorial, officials from scientific societies in the US and China call for the international community to develop criteria and standards for human germline editing.

The US National Institutes of Health is to review studies that have received private support for conflicts of interest, according to the New York Times.

In Science this week: the PsychENCODE Consortium reports on the molecular mechanisms of neuropsychiatric disorders, and more.